T1	intervention 0 11	Palbociclib
T2	eligibility 887 959	women with advanced disease which had progressed on one or two prior ETs
T3	control 1000 1017	palbociclib alone
T4	outcome-Measure 1107 1134	clinical benefit rate (CBR)
T5	outcome-Measure 1166 1197	progression-free survival (PFS)
T7	total-participants 1246 1249	115
T8	outcome 1280 1283	CBR
T9	cv-bin-percent 1288 1291	54%
T10	iv-bin-percent 1363 1366	60%
T11	outcome 1404 1414	Median PFS
T12	iv-cont-median 1419 1430	10.8 months
T13	cv-cont-median 1479 1489	6.5 months
T16	outcome 1629 1666	PFS advantage for combination therapy
